Vivus shares higher in pre-market on positive Qnexa results

Vivus shares were up in after-market trading on positive data from two late-stage clinical trials of Qnexa, an experimental treatment for weight loss, before trading begins Wednesday morning. The oral treatment is the Mountain View, Calif.-based company’s lead product.

NASDAQ:VVUS

Posted by admin on Sep 9th, 2009 and filed under Headlines, Pharma. You can follow any responses to this entry through the RSS 2.0. You can leave a response by filling following comment form or trackback to this entry from your site

Leave a Reply